secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001558370-24-014641
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q3 core revenue up 23% YoY to $8.1M; net loss $11.6M; guidance raised
-----------------------------------------------------------------------------

- Total Q3 revenue $8.2M (+2% YoY); core business revenue $8.1M (+23% YoY) driven by cell therapy growth of 39%.
- Net loss of $11.6M vs $11.3M in Q3 2023; EBITDA loss $13.0M; stock-based comp $3.4M.
- Signed 6 new SPL clients YTD, including Kamau, Legend Biotech, Be Bio; total SPL partners now 29.
- Full-year core revenue guidance raised to at least 5% growth; SPL program revenue affirmed at ~$6M.
- Cash and investments $196.6M at Sep 30; expects to end 2024 with ~$185M; evaluating potential AIM listing cancellation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024014641/0001558370-24-014641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837024014641/mxct-20241106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer